tradingkey.logo
tradingkey.logo

Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial

ReutersMar 11, 2026 5:02 PM

- Solid Biosciences Inc SLDB.O:

  • SOLID BIOSCIENCES PROVIDES INTERIM POSITIVE CLINICAL UPDATE ON PHASE 1/2 INSPIRE DUCHENNE TRIAL

  • SOLID BIOSCIENCES INC - SGT-003 GENERALLY WELL TOLERATED WITH ENCOURAGING SAFETY PROFILE IN 40 PARTICIPANTS

  • SOLID BIOSCIENCES INC - ROBUST MICRODYSTROPHIN EXPRESSION AND IMPROVED MUSCLE INTEGRITY OBSERVED AFTER SGT-003 TREATMENT

  • SOLID BIOSCIENCES INC - ANTICIPATES DOSING FIRST PARTICIPANT IN IMPACT DUCHENNE TRIAL IN Q1 2026

  • SOLID BIOSCIENCES: PLANS FOR ADDITIONAL MEETINGS WITH FDA IN H1 2026 FOR GUIDANCE ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR SGT-003

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI